Surrozen, Inc. has announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for SZN-8141. This milestone allows the company to advance its clinical development program for the treatment of diabetic macular edema (DME). The approval is significant as it enables Surrozen to begin dosing patients in a Phase 1b/2a clinical study, with initial data expected in the second half of 2027.
Surrozen, which operates in the biological products sector, focuses on developing innovative therapies. The company, trading under the ticker SRZN on the Nasdaq, has been working to address unmet medical needs in retinal diseases.
Background
Founded in Delaware, Surrozen, Inc. specializes in biological products, specifically those that do not include diagnostic substances. The company has been actively filing with the SEC, with its most recent filings including a Form 8-K on October 2, 2026, detailing the FDA clearance.
What the Filing Says
According to the filing dated October 2, 2026, Surrozen stated, "On October 2, 2026, Surrozen, Inc. announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development." This clearance follows the completion of the statutory 30-day review period.
The company also mentioned that SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody designed for intravitreal injection to treat DME. Surrozen anticipates dosing the first patient in the DUET clinical study in the fourth quarter of 2026.
Impact
The FDA clearance is expected to affect various stakeholders, including investors and patients suffering from diabetic macular edema. The approval also satisfies a milestone under Surrozen's March 2025 private placement agreement, potentially securing approximately $95.1 million in gross proceeds for the company.
What's Next
Following the second closing of the private placement, Surrozen plans to file a new registration statement on Form S-3 with the U.S. Securities and Exchange Commission to register shares of common stock and other securities. This filing is expected to occur no later than 30 days after the closing.